Melbourne, Australia; 26 October 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it will present at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.

The Wilsons Drug and Device Conference provides a forum for institutional investors to engage with ASX-listed healthcare companies through panel discussions, question-and-answer sessions, and 1 on 1 meetings.

Starpharma’s CEO, Dr Jackie Fairley, will provide an overview of the Company, including recent clinical results from its Phase 2 trials of DEP^® cabazitaxel and DEP^® irinotecan, as well as recently released data on its novel DEP^® radiotheranostics (radiodiagnostics and radiotherapeutics) programs.

At the conference, Dr Jackie Fairley will also participate in a panel discussion, ‘Expanding the scope for theranostics and radioligand therapies’, alongside Clarity Pharmaceuticals (ASX: CU6) and Telix Pharmaceuticals (ASX: TLX).

Dr Jackie Fairley, CEO, Starpharma, commented:

“Starpharma is delighted to present at the Wilsons Drug and Device Conference this week, highlighting our DEP^® platform, including our DEP^® radiotheranostics pipeline.

“Radiotheranostics is an innovative and rapidly growing area of cancer diagnosis and treatment, and Starpharma is pleased to participate in this panel, sharing recently reported data on Starpharma’s targeted DEP^® radiodiagnostic, DEP^® HER2-zirconium.”

Starpharma’s conference presentation is appended.

View or download the ASX Announcement, here.